These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 20506558

  • 1. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil.
    Zahr N, Arnaud L, Marquet P, Haroche J, Costedoat-Chalumeau N, Hulot JS, Funck-Brentano C, Piette JC, Amoura Z.
    Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study.
    Roland M, Barbet C, Paintaud G, Magdelaine-Beuzelin C, Diot E, Halimi JM, Lebranchu Y, Nivet H, Büchler M.
    Lupus; 2009 Apr; 18(5):441-7. PubMed ID: 19318398
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus.
    Sagcal-Gironella AC, Fukuda T, Wiers K, Cox S, Nelson S, Dina B, Sherwin CM, Klein-Gitelman MS, Vinks AA, Brunner HI.
    Semin Arthritis Rheum; 2011 Feb; 40(4):307-13. PubMed ID: 20655577
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N, Amoura Z, Debord J, Hulot JS, Saint-Marcoux F, Marquet P, Piette JC, Lechat P.
    Clin Pharmacokinet; 2008 Feb; 47(4):277-84. PubMed ID: 18336056
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus.
    Djabarouti S, Duffau P, Lazaro E, Chapouly C, Greib C, Viallard JF, Pellegrin JL, Saux MC, Breilh D.
    Expert Opin Pharmacother; 2010 Apr; 11(5):689-99. PubMed ID: 20210680
    [Abstract] [Full Text] [Related]

  • 6. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 7. The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients.
    Jirasiritham S, Sumethkul V, Mavichak V, Na-Bangchang K.
    Transplant Proc; 2004 Sep; 36(7):2076-8. PubMed ID: 15518751
    [Abstract] [Full Text] [Related]

  • 8. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
    Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.
    J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
    [Abstract] [Full Text] [Related]

  • 9. Best single time points as surrogates to the tacrolimus and mycophenolic acid area under the curve in adult liver transplant patients beyond 12 months of transplantation.
    Mardigyan V, Tchervenkov J, Metrakos P, Barkun J, Deschenes M, Cantarovich M.
    Clin Ther; 2005 Apr; 27(4):463-9. PubMed ID: 15922819
    [Abstract] [Full Text] [Related]

  • 10. Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.
    Mino Y, Naito T, Shimoyama K, Ogawa N, Kawakami J.
    J Clin Pharm Ther; 2012 Apr; 37(2):217-20. PubMed ID: 21517926
    [Abstract] [Full Text] [Related]

  • 11. Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.
    Daleboudt GM, Reinders ME, den Hartigh J, Huizinga TW, Rabelink AJ, de Fijter JW, Berger SP.
    Lupus; 2013 Feb; 22(2):171-9. PubMed ID: 23257398
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.
    Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.
    Liver Transpl; 2007 Nov; 13(11):1570-5. PubMed ID: 17969194
    [Abstract] [Full Text] [Related]

  • 13. Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study.
    Djabarouti S, Breilh D, Duffau P, Lazaro E, Greib C, Caubet O, Saux MC, Pellegrin JL, Viallard JF.
    Arthritis Res Ther; 2010 Nov; 12(6):R217. PubMed ID: 21176194
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.
    Woillard JB, Bader-Meunier B, Salomon R, Ranchin B, Decramer S, Fischbach M, Berard E, Guigonis V, Harambat J, Dunand O, Tenenbaum J, Marquet P, Saint-Marcoux F.
    Br J Clin Pharmacol; 2014 Oct; 78(4):867-76. PubMed ID: 24697955
    [Abstract] [Full Text] [Related]

  • 15. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y, Naito T, Shimoyama K, Ogawa N, Kawakami J.
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil.
    Neumann I, Fuhrmann H, Fang IF, Jaeger A, Bayer P, Kovarik J.
    Nephrol Dial Transplant; 2008 Nov; 23(11):3514-20. PubMed ID: 18586766
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.
    Nannini C, Crowson CS, Matteson EL, Moder KG.
    Lupus; 2009 Apr; 18(5):394-9. PubMed ID: 19318390
    [Abstract] [Full Text] [Related]

  • 19. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients.
    Kaczmarek I, Bigdeli AK, Vogeser M, Mueller T, Beiras-Fernandez A, Kaczmarek P, Schmoeckel M, Meiser B, Reichart B, Ueberfuhr P.
    Ther Drug Monit; 2008 Aug; 30(4):419-27. PubMed ID: 18641552
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.